Literature DB >> 27287334

Atypical Huntington's disease with the clinical presentation of behavioural variant of frontotemporal dementia.

Stanislav Sutovsky1, Tomas Smolek2, Irina Alafuzoff3, Andrej Blaho1, Vojtech Parrak2,4, Peter Turcani1, Michal Palkovic5, Robert Petrovic6, Michal Novak2, Norbert Zilka7,8.   

Abstract

Huntington's disease is an incurable, adult-onset, autosomal dominant inherited disorder caused by an expanded trinucleotide repeat (CAG). In this study, we describe a Huntington's disease patient displaying clinical symptoms of the behavioural variant of frontotemporal dementia in the absence of tremor and ataxia. The clinical onset was at the age of 36 years and the disease progressed slowly (18 years). Genetic testing revealed expanded trinucleotide CAG repeats in the Huntingtin gene, together with a Glu318Gly polymorphism in presenilin 1. Neuropathological assessment revealed extensive amyloid β (Aβ) aggregates in all cortical regions. No inclusions displaying hyperphosphorylated tau or phosphorylated transactive response DNA-binding protein 43 (TDP43) were found. A high number of p62 (sequestosome 1) immunopositive intranuclear inclusions were seen mainly in the cortex, while subcortical areas were affected to a lesser extent. Confocal microscopy revealed that the majority of p62 intranuclear lesions co-localised with the fused-in-sarcoma protein (FUS) immunostaining. The morphology of the inclusions resembled intranuclear aggregates in Huntington's disease. The presented proband suffered from Huntington's disease showed atypical distribution of FUS positive intranuclear aggregates in the cortical areas with concomitant Alzheimer's disease pathology.

Entities:  

Keywords:  Amyloid; Behavioural variant FTD; FUS; Huntingtin; Intranuclear inclusions

Mesh:

Substances:

Year:  2016        PMID: 27287334     DOI: 10.1007/s00702-016-1579-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  23 in total

1.  The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease.

Authors:  B Dermaut; M Cruts; A J Slooter; S Van Gestel; C De Jonghe; H Vanderstichele; E Vanmechelen; M M Breteler; A Hofman; C M van Duijn; C Van Broeckhoven
Journal:  Am J Hum Genet       Date:  1999-01       Impact factor: 11.025

2.  Imaging signatures of molecular pathology in behavioral variant frontotemporal dementia.

Authors:  Jennifer L Whitwell; Clifford R Jack; Joseph E Parisi; David S Knopman; Bradley F Boeve; Ronald C Petersen; Dennis W Dickson; Keith A Josephs
Journal:  J Mol Neurosci       Date:  2011-05-10       Impact factor: 3.444

3.  The RNA-binding protein FUS/TLS is a common aggregate-interacting protein in polyglutamine diseases.

Authors:  Hiroshi Doi; Shigeru Koyano; Yume Suzuki; Nobuyuki Nukina; Yoshiyuki Kuroiwa
Journal:  Neurosci Res       Date:  2009-10-13       Impact factor: 3.304

Review 4.  Neuroimaging in frontotemporal dementia.

Authors:  Jonathan D Rohrer; Howard J Rosen
Journal:  Int Rev Psychiatry       Date:  2013-04

5.  RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells.

Authors:  Hiroshi Doi; Kazumasa Okamura; Peter O Bauer; Yoshiaki Furukawa; Hideaki Shimizu; Masaru Kurosawa; Yoko Machida; Haruko Miyazaki; Kenichi Mitsui; Yoshiyuki Kuroiwa; Nobuyuki Nukina
Journal:  J Biol Chem       Date:  2007-12-31       Impact factor: 5.157

6.  The E318G substitution in PSEN1 gene is not connected with Alzheimer's disease in a large Polish cohort.

Authors:  Cezary Zekanowski; Beata Pepłońska; Maria Styczyńska; Dorota Religa; Anna Pfeffer; Krzysztof Czyzewski; Tomasz Gabryelewicz; Aleksandra Szybińska; Beata Kijanowska-Haładyna; Sławomira Kotapka-Minc; Elzbieta Łuczywek; Anna Barczak; Bogusław Wasiak; Małgorzata Chodakowska-Zebrowska; Izabela Przekop; Jacek Kuźnicki; Maria Barcikowska
Journal:  Neurosci Lett       Date:  2004-03-11       Impact factor: 3.046

7.  Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions.

Authors:  Utako Nagaoka; Ken Kim; Nihar Ranjan Jana; Hiroshi Doi; Mieko Maruyama; Kenichi Mitsui; Fumitaka Oyama; Nobuyuki Nukina
Journal:  J Neurochem       Date:  2004-10       Impact factor: 5.372

Review 8.  Frontotemporal lobar degeneration: clinical and pathological relationships.

Authors:  Julie Snowden; David Neary; David Mann
Journal:  Acta Neuropathol       Date:  2007-06-14       Impact factor: 17.088

Review 9.  Clinical Aspects of Huntington's Disease.

Authors:  Rhia Ghosh; Sarah J Tabrizi
Journal:  Curr Top Behav Neurosci       Date:  2015

10.  Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium.

Authors:  Irina Alafuzoff; Thomas Arzberger; Safa Al-Sarraj; Istvan Bodi; Nenad Bogdanovic; Heiko Braak; Orso Bugiani; Kelly Del-Tredici; Isidro Ferrer; Ellen Gelpi; Giorgio Giaccone; Manuel B Graeber; Paul Ince; Wouter Kamphorst; Andrew King; Penelope Korkolopoulou; Gábor G Kovács; Sergey Larionov; David Meyronet; Camelia Monoranu; Piero Parchi; Efstratios Patsouris; Wolfgang Roggendorf; Danielle Seilhean; Fabrizio Tagliavini; Christine Stadelmann; Nathalie Streichenberger; Dietmar R Thal; Stephen B Wharton; Hans Kretzschmar
Journal:  Brain Pathol       Date:  2008-03-26       Impact factor: 6.508

View more
  1 in total

1.  An unusual presentation of Huntington's disease.

Authors:  Martin Schulze Westhoff; Alma Osmanovic; Catharina Meissner; Johannes Heck; Nima Mahmoudi; Corinna Hendrich; Georg Berding; Johanna Seifert; Stefan Bleich; Helge Frieling; Tillmann Krüger; Adrian Groh
Journal:  Clin Case Rep       Date:  2021-07-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.